BREAST CANCER

>

Latest News

Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer

December 22nd 2024

During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.

Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment

December 20th 2024

The Promise of Metabolomics to Transform Breast Cancer Screening
The Promise of Metabolomics to Transform Breast Cancer Screening

December 19th 2024

Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer

December 13th 2024

ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer

December 13th 2024

Latest CME Events & Activities

Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs

View More

Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs

View More

Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings

View More

School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio

View More

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

View More

Annual Hawaii Cancer Conference

January 25-26, 2025

Register Now!

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

View More

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

Register Now!

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice

View More

Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions

View More

Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations

View More

Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer

View More

How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment

View More

Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

24th Annual International Congress on the Future of Breast Cancer® West

July 18-19, 2025

Register Now!

24th Annual International Congress on the Future of Breast Cancer® East

July 11-12, 2025

Register Now!

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

View More

Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West

View More

23rd Annual School of Breast Oncology

November 6-8, 2025

Register Now!

Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments

View More

School of Breast Oncology® (SOBO) Slide & Lecture Library

Joyce O’Shaughnessy, MD

View More